BioSyent Inc. (CVE:RX – Get Free Report) shares crossed above its 50 day moving average during trading on Wednesday . The stock has a 50 day moving average of C$14.23 and traded as high as C$14.75. BioSyent shares last traded at C$14.66, with a volume of 1,258 shares changing hands.
BioSyent Stock Down 0.6%
The company has a quick ratio of 6.91, a current ratio of 1.89 and a debt-to-equity ratio of 11.66. The stock has a market capitalization of C$166.13 million, a P/E ratio of 18.70 and a beta of 0.99. The company has a fifty day moving average price of C$14.23 and a 200-day moving average price of C$14.40.
Insider Activity
In other news, Director Seyed Ahmad Ashrafi sold 1,884 shares of the stock in a transaction that occurred on Tuesday, June 30th. The stock was sold at an average price of C$14.65, for a total transaction of C$27,600.60. Following the completion of the transaction, the director directly owned 37,261 shares in the company, valued at approximately C$545,873.65. This represents a 4.81% decrease in their position. Over the last 90 days, insiders sold 4,358 shares of company stock worth $63,132. 33.65% of the stock is owned by corporate insiders.
BioSyent Company Profile
BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia. It offers Tibella, a hormone replacement therapy consisting of tibolone; Inofolic, a natural health product to address polycystic ovarian syndrome symptoms; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by aging, menopause, stress, and chemotherapy; and Gelclair, a gel formulated to aid the pain or oral mucositis.
Read More
- Five stocks we like better than BioSyent
- Why SK hynix Could Be the Best AI Chip Stock to Buy Now
- Seagate Technology Stock Surges as Earnings Beat Silences AI Doubters
- Alphabet Is Down 18% From Its High After a Stellar Quarter—Overdone, or More Downside Ahead?
- Why Bloom Energy May Be the Most Important AI Infrastructure Stock
Receive News & Ratings for BioSyent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSyent and related companies with MarketBeat.com's FREE daily email newsletter.
